Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Xtant Medical Holdings (XTNT) over the last 17 years, with Q3 2025 value amounting to $10.4 million.

  • Xtant Medical Holdings' Cash & Equivalents rose 5767.13% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 5767.13%. This contributed to the annual value of $6.2 million for FY2024, which is 846.89% up from last year.
  • Latest data reveals that Xtant Medical Holdings reported Cash & Equivalents of $10.4 million as of Q3 2025, which was up 5767.13% from $6.9 million recorded in Q2 2025.
  • Xtant Medical Holdings' Cash & Equivalents' 5-year high stood at $20.3 million during Q2 2021, with a 5-year trough of $4.1 million in Q2 2023.
  • In the last 5 years, Xtant Medical Holdings' Cash & Equivalents had a median value of $8.7 million in 2023 and averaged $11.3 million.
  • As far as peak fluctuations go, Xtant Medical Holdings' Cash & Equivalents surged by 67928.24% in 2021, and later tumbled by 7491.36% in 2023.
  • Xtant Medical Holdings' Cash & Equivalents (Quarter) stood at $18.2 million in 2021, then increased by 11.26% to $20.3 million in 2022, then crashed by 71.84% to $5.7 million in 2023, then grew by 8.47% to $6.2 million in 2024, then skyrocketed by 67.77% to $10.4 million in 2025.
  • Its Cash & Equivalents stands at $10.4 million for Q3 2025, versus $6.9 million for Q2 2025 and $5.0 million for Q1 2025.